Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Cellular Biomedicine Raises $30.6 Million from Sailing Capital

publication date: Feb 5, 2018

Cellular Biomedicine, a China-US biopharma, announced a $30.6 million investment from Sailing Capital Overseas. Sailing Capital is a Shanghai-Hong Kong PE investor focused on China cross-border situations. CBMG is developing a CAR-T immunotherapy for cancer indications, which it acquired from Beijing's PLA General Hospital (the 301) in 2015. The immunotherapy is currently being tested in three China clinical trials. CBMG's latest funding brings its cash position to about $60 million. More details....

Stock Symbol: (NSDQ: CBMG)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.